## Raju C Reddy

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/65445/publications.pdf

Version: 2024-02-01

201674 302126 2,290 39 27 39 h-index citations g-index papers 39 39 39 3613 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Cigarette smoke downregulates Nur77 to exacerbate inflammation in chronic obstructive pulmonary disease (COPD). PLoS ONE, 2020, 15, e0229256.	2.5	8
2	<p>Clucocorticoid Receptor α Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD. International Journal of COPD, 2020, Volume 15, 125-134.</p>	2.3	12
3	Bidirectional interaction of airway epithelial remodeling and inflammation in asthma. Clinical Science, 2020, 134, 1063-1079.	4.3	76
4	Molecular, chemical, and structural characterization of prostaglandin A2 as a novel agonist for Nur77. Biochemical Journal, 2019, 476, 2757-2767.	3.7	22
5	Key Functions and Therapeutic Prospects of Nur77 in Inflammation Related Lung Diseases. American Journal of Pathology, 2019, 189, 482-491.	3.8	33
6	PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma. Nuclear Receptor Research, 2018, 5, .	2.5	51
7	Identification and Molecular Characterization of Peroxisome Proliferator-Activated Receptor $\hat{l}'$ as a Novel Target for Covalent Modification by 15-Deoxy- $\hat{l}''$ < sup>12,14-prostaglandin J <sub>2</sub> . ACS Chemical Biology, 2018, 13, 3269-3278.	3.4	10
8	Airway Epithelial Cell Peroxisome Proliferator–Activated Receptor γ Regulates Inflammation and Mucin Expression in Allergic Airway Disease. Journal of Immunology, 2018, 201, 1775-1783.	0.8	29
9	Role of GPx3 in PPAR $\hat{I}^3$ -induced protection against COPD-associated oxidative stress. Free Radical Biology and Medicine, 2018, 126, 350-357.	2.9	40
10	Transforming growth factor $\hat{l}^2$ suppresses peroxisome proliferator-activated receptor $\hat{l}^3$ expression via both SMAD binding and novel TGF- $\hat{l}^2$ inhibitory elements. Biochemical Journal, 2017, 474, 1531-1546.	3.7	44
11	Emerging pharmaceutical therapies for COPD. International Journal of COPD, 2017, Volume 12, 2141-2156.	2.3	44
12	PPAR Agonists for the Prevention and Treatment of Lung Cancer. PPAR Research, 2017, 2017, 1-8.	2.4	44
13	PPAR <i>γ</i> in Bacterial Infections: A Friend or Foe?. PPAR Research, 2016, 2016, 1-7.	2.4	21
14	PPAR <i<math>\hat{I}^3as a Novel Therapeutic Target in Lung Cancer. PPAR Research, 2016, 2016, 1-7.</i<math>	2.4	37
15	Nitrated Fatty Acids Reverse Cigarette Smoke-Induced Alveolar Macrophage Activation and Inhibit Protease Activity via Electrophilic S-Alkylation. PLoS ONE, 2016, 11, e0153336.	2.5	18
16	Down-regulated Peroxisome Proliferator-activated Receptor Î <sup>3</sup> (PPARÎ <sup>3</sup> ) in Lung Epithelial Cells Promotes a PPARÎ <sup>3</sup> Agonist-reversible Proinflammatory Phenotype in Chronic Obstructive Pulmonary Disease (COPD). Journal of Biological Chemistry, 2014, 289, 6383-6393.	3.4	63
17	Nitrated fatty acids reverse pulmonary fibrosis by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages. FASEB Journal, 2014, 28, 5299-5310.	0.5	66
18	The Nitrated Fatty Acid 10-Nitro-Oleate Attenuates Allergic Airway Disease. Journal of Immunology, 2013, 191, 2053-2063.	0.8	39

#	Article	IF	Citations
19	Effects of JAM-A deficiency or blocking antibodies on neutrophil migration and lung injury in a murine model of ALI. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 303, L758-L766.	2.9	40
20	The Nitrated Fatty Acid 10-Nitro-oleate Diminishes Severity of LPS-Induced Acute Lung Injury in Mice. PPAR Research, 2012, 2012, 1-12.	2.4	24
21	PPARs: Regulators and Translational Targets in the Lung. PPAR Research, 2012, 2012, 1-2.	2.4	6
22	Murine Model of Allergen Induced Asthma. Journal of Visualized Experiments, 2012, , e3771.	0.3	35
23	Endothelial Cell Peroxisome Proliferator–Activated Receptor γ Reduces Endotoxemic Pulmonary Inflammation and Injury. Journal of Immunology, 2012, 189, 5411-5420.	0.8	53
24	The Effects of Bariatric Surgery on Asthma Severity. Obesity Surgery, 2011, 21, 200-206.	2.1	55
25	Effects of sepsis on neutrophil chemotaxis. Current Opinion in Hematology, 2010, 17, 18-24.	2.5	85
26	Leukotriene B4 Is a Physiologically Relevant Endogenous Peroxisome Proliferator-activated Receptor-α Agonist. Journal of Biological Chemistry, 2010, 285, 22067-22074.	3.4	104
27	Nrf2 and PPARÎ <sup>3</sup> . American Journal of Respiratory and Critical Care Medicine, 2010, 182, 134-135.	5.6	36
28	Curcumin is not a ligand for peroxisome proliferator-activated receptor- $\hat{l}^3$ . Gene Therapy and Molecular Biology, 2009, 13, 20-25.	1.3	19
29	Chemotherapeutic Drugs Induce PPAR-γ Expression and Show Sequence-Specific Synergy with PPAR-γ Ligands in Inhibition of Non–Small Cell Lung Cancer. Neoplasia, 2008, 10, 597-603.	5.3	42
30	Immunomodulatory Role of PPAR- $\hat{l}^3$ in Alveolar Macrophages. Journal of Investigative Medicine, 2008, 56, 522-527.	1.6	62
31	PPAR- $\hat{l}^3$ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L891-L901.	2.9	182
32	Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor- $\hat{l}^3$ . Blood, 2008, 112, 4250-4258.	1.4	87
33	Stimulatory Effects of Peroxisome Proliferator-Activated Receptor- <mml:math id="E1" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>î³</mml:mi></mml:math> on Fc <mml:math id="E2" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>î³</mml:mi>c/mml:mi&gt;c/mml:math&gt;Receptor-Mediated Phagocytosis by Alveolar Macrophages.</mml:math>	2.4	22
34	Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma. Respiratory Research, 2007, 8, 90.	3.6	44
35	Differential Protein Expression Profiling by iTRAQâ^'2DLCâ^'MS/MS of Lung Cancer Cells Undergoing Epithelial-Mesenchymal Transition Reveals a Migratory/Invasive Phenotype. Journal of Proteome Research, 2006, 5, 1143-1154.	3.7	258
36	Peroxisome Proliferator-activated Receptor-Â as a Regulator of Lung Inflammation and Repair. Proceedings of the American Thoracic Society, 2005, 2, 226-231.	3.5	122

## Raju C Reddy

#	Article	IF	CITATION
37	PPAR- $\hat{l}^3$ Activation Inhibits Angiogenesis by Blocking ELR+CXC Chemokine Production in Non-small Cell Lung Cancer. Neoplasia, 2005, 7, 294-301.	5.3	98
38	Deactivation of murine alveolar macrophages by peroxisome proliferator-activated receptor- $\hat{l}^3$ ligands. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 286, L613-L619.	2.9	69
39	Peroxisome proliferator-activated receptor- $\hat{l}^3$ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene, 2004, 23, 100-108.	5.9	190